Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-25
Target enrollment:
Participant gender:
Summary
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
Phase:
PHASE1
Details
Lead Sponsor:
GlaxoSmithKline